New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
08:17 EDTSNY, MACKMerrimack completes enrollment in Phase 2 study of MM-121 in collaboration with Sanofi
Merrimack Pharmaceuticals (MACK) announced that the last patient has been enrolled in a Phase 2, open-label, randomized clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, in combination with paclitaxel versus paclitaxel alone in patients with platinum-resistant or platinum refractory advanced ovarian cancers. MM-121 is being developed in collaboration with Sanofi (SNY).
News For MACK;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
15:17 EDTMACKMerrimack to host analyst day
Subscribe for More Information
December 12, 2014
08:05 EDTMACKMerrimack presents research on MM-398, MM-302, MM-121
Subscribe for More Information
December 9, 2014
11:19 EDTSNYSanofi reportedly ready to make acquisitions in animal medicine, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use